Entering text into the input field will update the search result below

ChromaDex's Niagen supplementation shows promise in Parkinson’s disease trial

Mar. 02, 2022 7:34 AM ETChromaDex Corporation (CDXC)By: Ravikash, SA News Editor

Brain problems. Parkinson and alzheimer desease. Mental health. Stroke, synapses and neurnons interaction

Naeblys/iStock via Getty Images

  • ChromaDex (NASDAQ:CDXC) said a phase 1 trial showed that its Niagen ingredient supplementation significantly increased brain nicotinamide adenine dinucleotide (NAD) levels, and resulted in altered cerebral energy metabolism and decreased levels of inflammatory cytokines in patients with Parkinson’s disease (PD).

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.